fbpx An update on Mmr | Page 294 | Science in the net

An update on Mmr

Primary tabs

Read time: 1 min

Measles, mumps and rubella outbreaks still represent an healthcare issue, even though major advancements have been done towards their eradication. A poor inclination towards Mmr (measles-mumps-rubella) vaccination may constitute a major cause of increased risk to contract one of these diseases amongst specific population groups like migrants, alternative medicine users, some religious groups, healthcare professionals.
Information on Mmr vaccines coverage amongst these and others “hard-to-reach” groups was included in a document made and published Ecdc in range of the European project Venice II (Vaccine European New Integrated Collaboration Effort II). Main aim of the document was to provide a complete review of measles, mumps and rubella focuses which have been reported in the last twenty years in Europe.

Autori: 
Sezioni: 
Indice: 
Vaccination

prossimo articolo

Seventh Framework Programme: data on Italian participation

Research and development expenditure in Italy amounts to approximately 17.53 billion euro.
The proportion of GDP devoted to R&D is 1.18%, which is lower than the European average standing at around 1.8% and higher only compared to countries such as Hungary, Poland and Greece. Trying to compensate for the scarce resources that governments have devoted and continue to devote to research, Italian researchers seek to obtain funds through the several funding options provided by the European Community.